ArticleBritish journal of cancer2000
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
Article in British journal of cancer, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.PloS one · 2015Pooled it
- A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Trial
- Review
- Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Combined detection of dickkopf-1 subtype classification autoantibodies as biomarkers for the diagnosis and prognosis of non-small cell lung cancer.OncoTargets and therapy · 2017Article
- Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer.Journal of ovarian research · 2014Article
- Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.Journal of cancer research and clinical oncology · 2013Article
- p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.Journal of cancer research and clinical oncology · 2013Article
- Humoral innate immune response and disease.Clinical immunology (Orlando, Fla.) · 2012Review
- p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2010Article
- Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients.Experimental and therapeutic medicine · 2010Article
- Autoantibodies to tumor-associated antigens in breast carcinoma.Journal of oncology · 2010Article
- Retracted: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.Gynecologic oncology · 2009Article
- p53 autoantibodies, cytokine levels and ovarian carcinogenesis.Gynecologic oncology · 2009Article
- Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.Journal of oncology · 2009Article
- Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.PloS one · 2008Article
- Immunologic aspect of ovarian cancer and p53 as tumor antigen.Journal of translational medicine · 2005Article
- Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.Clinical and experimental immunology · 2003Review
- P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.World journal of gastroenterology · 2002Article
- Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.The Journal of clinical investigation · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum autoantibodies against the p53 protein (p53 AAb) were analysed with a newly developed enzyme-linked immunosorbent assay (ELISA) based on highly purified and renatured p53. In a hospital-based cohort study, preoperative sera from 113 patients with ovarian cancer, 15 patients with borderline tumours and 117 patients with benign tumours of the ovaries were studied. The prevalence of p53 AAb in patients with invasive cancer was 19% (21/113). No p53 AAb were found in patients with borderline lesions or benign tumours. The ELISA had a specificity for malignancy of 99% (1 of 117; false-positive from a patient with severe diabetes mellitus) and a likelihood ratio (LR+) for a positive test result of 21.7 (elevated CA125 and malignancy: LR+ 3.7). p53 AAb were only detectable in patients with immunohistochemical staining of nuclear p53 in the tumour (P = 0.006). Presence of p53 AAb positively correlated with tumour stage (P = 0.034) and grade (P = 0.009). Kaplan-Meier analysis showed both a shortened overall survival (P = 0.0016, log-rank) and relapse-free survival (P = 0.055) for p53 AAb-positive patients (median follow-up 22 months). High titres related to even worse prognosis. p53 AAb independently related to poor survival adjusting for stage (P = 0.026), grade (P = 0.029) and residual disease after surgery (P = 0.005). Preoperative findings of adnexal mass with serum p53 AAb are strongly suggestive of an aggressive invasive ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.